<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Although some trials have allowed matched or single human leukocyte antigen (HLA)-mismatched related donors (mmRDs) along with HLA-matched sibling donors (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSDs</z:e>) for pediatric bone marrow transplantation in early-stage <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e>, whether mmRD grafts lead to similar outcomes is not known </plain></SENT>
<SENT sid="1" pm="."><plain>We compared patients &lt; 18 years old reported to the Center for International Blood and Marrow Transplant Research with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo>, <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo>, <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo>, and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> undergoing allogeneic T-replete, myeloablative bone marrow transplantation between 1993 and 2006 </plain></SENT>
<SENT sid="2" pm="."><plain>In total, patients receiving bone marrow from 1208 MSDs, 266 8/8 allelic-matched unrelated donors (URDs), and 151 0-1 HLA-antigen mmRDs were studied </plain></SENT>
<SENT sid="3" pm="."><plain>Multivariate analysis showed that recipients of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSD</z:e> transplants had less transplantation-related mortality, <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD), and <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD, along with better disease-free and overall survival than the URD and mmRD groups </plain></SENT>
<SENT sid="4" pm="."><plain>No differences were observed in transplant-related mortality, <z:hpo ids='HP_0011009'>acute</z:hpo> and <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD, relapse, disease-free survival, or overall survival between the mmRD and URD groups </plain></SENT>
<SENT sid="5" pm="."><plain>These data show that mmRD and 8/8 URD outcomes are similar, whereas <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSD</z:e> outcomes are superior to the other 2 sources </plain></SENT>
<SENT sid="6" pm="."><plain>Whether allele level typing could identify mmRD recipients with better outcomes will not be known unless centers alter practice and type mmRD at the allele level </plain></SENT>
</text></document>